-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Bioventus (NYSE:BVS) Trading Down 7.4%
Bioventus (NYSE:BVS) Trading Down 7.4%
Shares of Bioventus Inc. (NYSE:BVS – Get Rating) dropped 7.4% during trading on Thursday . The company traded as low as $7.55 and last traded at $7.66. Approximately 4,531 shares were traded during trading, a decline of 95% from the average daily volume of 82,552 shares. The stock had previously closed at $8.27.
Analyst Ratings Changes
Separately, Morgan Stanley boosted their target price on Bioventus from $11.00 to $12.00 and gave the company an "overweight" rating in a research report on Friday, August 12th.
Get Bioventus alerts:Bioventus Stock Performance
The company has a current ratio of 1.39, a quick ratio of 1.05 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $603.34 million, a PE ratio of -22.47 and a beta of 2.11. The firm's 50-day simple moving average is $8.01 and its 200-day simple moving average is $9.95.
Bioventus (NYSE:BVS – Get Rating) last announced its quarterly earnings results on Thursday, August 11th. The company reported $0.10 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.14 by ($0.04). The firm had revenue of $140.33 million during the quarter, compared to analysts' expectations of $140.01 million. Bioventus had a negative net margin of 4.26% and a positive return on equity of 10.35%. During the same quarter in the previous year, the firm posted $0.16 EPS. On average, research analysts predict that Bioventus Inc. will post 0.54 earnings per share for the current year.Institutional Trading of Bioventus
A number of hedge funds have recently added to or reduced their stakes in BVS. Royce & Associates LP raised its holdings in shares of Bioventus by 0.8% in the 2nd quarter. Royce & Associates LP now owns 1,958,785 shares of the company's stock valued at $13,359,000 after purchasing an additional 15,602 shares in the last quarter. Nuance Investments LLC raised its stake in Bioventus by 6.0% in the first quarter. Nuance Investments LLC now owns 1,352,101 shares of the company's stock worth $19,065,000 after buying an additional 77,061 shares in the last quarter. First Light Asset Management LLC lifted its holdings in Bioventus by 49.6% during the second quarter. First Light Asset Management LLC now owns 1,348,460 shares of the company's stock worth $9,196,000 after buying an additional 446,935 shares during the period. Tamarack Advisers LP boosted its position in Bioventus by 82.3% during the 4th quarter. Tamarack Advisers LP now owns 875,000 shares of the company's stock valued at $12,679,000 after acquiring an additional 395,000 shares in the last quarter. Finally, Wasatch Advisors Inc. purchased a new position in shares of Bioventus in the 1st quarter valued at $9,967,000. 44.62% of the stock is owned by hedge funds and other institutional investors.
Bioventus Company Profile
(Get Rating)
Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
Featured Stories
- Get a free copy of the StockNews.com research report on Bioventus (BVS)
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 2 Reasons Netflix Might Have Just Bottomed Out
- Has 3M Reached the Point of Being so Bad It's Good?
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Bioventus Inc. (NYSE:BVS – Get Rating) dropped 7.4% during trading on Thursday . The company traded as low as $7.55 and last traded at $7.66. Approximately 4,531 shares were traded during trading, a decline of 95% from the average daily volume of 82,552 shares. The stock had previously closed at $8.27.
Bioventus Inc.(纽约证券交易所代码：BVS-GET评级)的股价在周四的交易中下跌7.4%。该公司股价低至7.55美元，最新报7.66美元。当日成交量约为4,531股，较日均成交量82,552股下降95%。该股此前收盘价为8.27美元。
Analyst Ratings Changes
分析师评级发生变化
Separately, Morgan Stanley boosted their target price on Bioventus from $11.00 to $12.00 and gave the company an "overweight" rating in a research report on Friday, August 12th.
另外，摩根士丹利在8月12日(周五)的一份研究报告中将Bioventus的目标价从11.00美元上调至12.00美元，并给予该公司“增持”评级。
Bioventus Stock Performance
Bioventus股票表现
The company has a current ratio of 1.39, a quick ratio of 1.05 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $603.34 million, a PE ratio of -22.47 and a beta of 2.11. The firm's 50-day simple moving average is $8.01 and its 200-day simple moving average is $9.95.
该公司的流动比率为1.39，速动比率为1.05，债务权益比率为0.68。该公司市值为6.0334亿美元，市盈率为-22.47，贝塔系数为2.11。该公司的50日简单移动均线切入位为8.01美元，200日简单移动均线切入位为9.95美元。
Institutional Trading of Bioventus
Bioventus的制度性交易
A number of hedge funds have recently added to or reduced their stakes in BVS. Royce & Associates LP raised its holdings in shares of Bioventus by 0.8% in the 2nd quarter. Royce & Associates LP now owns 1,958,785 shares of the company's stock valued at $13,359,000 after purchasing an additional 15,602 shares in the last quarter. Nuance Investments LLC raised its stake in Bioventus by 6.0% in the first quarter. Nuance Investments LLC now owns 1,352,101 shares of the company's stock worth $19,065,000 after buying an additional 77,061 shares in the last quarter. First Light Asset Management LLC lifted its holdings in Bioventus by 49.6% during the second quarter. First Light Asset Management LLC now owns 1,348,460 shares of the company's stock worth $9,196,000 after buying an additional 446,935 shares during the period. Tamarack Advisers LP boosted its position in Bioventus by 82.3% during the 4th quarter. Tamarack Advisers LP now owns 875,000 shares of the company's stock valued at $12,679,000 after acquiring an additional 395,000 shares in the last quarter. Finally, Wasatch Advisors Inc. purchased a new position in shares of Bioventus in the 1st quarter valued at $9,967,000. 44.62% of the stock is owned by hedge funds and other institutional investors.
一些对冲基金最近增持或减持了BVS的股份。Royce&Associates LP在第二季度将Bioventus的股票持有量增加了0.8%。Royce&Associates LP在上个季度额外购买了15,602股后，现在拥有1,958,785股该公司股票，价值13,359,000美元。Nuance Investments LLC在第一季度将其在Bioventus的持股比例提高了6.0%。Nuance Investments LLC现在拥有1,352,101股该公司股票，价值19,065,000美元，上个季度又购买了77,061股。第一轻资产管理有限责任公司在第二季度增持了49.6%的Bioventus股份。First Light Asset Management LLC在此期间又购买了446,935股，现在拥有1,348,460股该公司股票，价值9,196,000美元。Tamarack Advisers LP在第四季度将其在Bioventus的头寸提高了82.3%。Tamarack Advisers LP在上个季度增持了395,000股后，现在拥有875,000股该公司股票，价值12,679,000美元。最后，Wasatch Advisors Inc.在第一季度购买了Bioventus的新头寸，价值996.7万美元。44.62%的股票由对冲基金和其他机构投资者持有。
Bioventus Company Profile
Bioventus公司简介
(Get Rating)
(获取评级)
Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
Bioventus公司是一家医疗设备公司，专注于开发临床治疗方法并将其商业化，这些治疗方法在美国和国际上参与并增强了人体的自然愈合过程。该公司的产品组合包括疼痛治疗，其中包括非手术关节疼痛注射疗法，以及周围神经刺激产品。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Bioventus (BVS)
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
- 2 Reasons Netflix Might Have Just Bottomed Out
- Has 3M Reached the Point of Being so Bad It's Good?
- 免费获取StockNews.com关于Bioventus(BVS)的研究报告
- 为什么医疗产品制造商Repligen可能成为潜在收购对象
- 在10%的水平上，Arbor Realty Trust的股息值得吗？
- 投资者应关注RF Industries
- Netflix可能刚刚触底的两个原因
- 3M已经到了坏到好的地步了吗？
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
收到《Bioventus Daily》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Bioventus和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧